Monopar Therapeutics Inc.
MNPRNASDAQHealthcare● Active
$60.61
+$1.13(+1.90%)
Market Cap$406030027
P/E Ratio—
52W High$105
52W Low$29.18
Monopar Therapeutics Inc. (MNPR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MNPR · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$0.46
Est. -$1.06 · +56.6%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
MNPR reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.67 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 14, 2026 | -$1.06 | -$0.46 | +56.6% | — | — | — |
| ▼ Q1 FY2026 | Mar 27, 2026 | -$0.51 | -$0.61 | -19.1% | — | — | — |
| ▼ Q4 FY2025 | Nov 13, 2025 | -$0.46 | -$0.48 | -4.3% | — | — | — |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$0.47 | -$0.35 | +25.5% | — | — | — |
| ▲ Q2 FY2025 | May 13, 2025 | -$0.65 | -$0.38 | +41.5% | — | — | — |
| ▼ Q1 FY2025 | Mar 31, 2025 | -$0.36 | -$2.23 | -519.4% | — | — | — |
| ▲ Q4 FY2024 | Nov 8, 2024 | -$0.46 | -$0.37 | +19.6% | — | — | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.67
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Beat
EPS Actual
-$0.46
EPS Est.
-$1.06
EPS Surpr.
+56.6%
Revenue
—
Q1 FY2026
Mar 27, 2026Miss
EPS Actual
-$0.61
EPS Est.
-$0.51
EPS Surpr.
-19.1%
Revenue
—
Q4 FY2025
Nov 13, 2025Miss
EPS Actual
-$0.48
EPS Est.
-$0.46
EPS Surpr.
-4.3%
Revenue
—
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$0.35
EPS Est.
-$0.47
EPS Surpr.
+25.5%
Revenue
—
Q2 FY2025
May 13, 2025Beat
EPS Actual
-$0.38
EPS Est.
-$0.65
EPS Surpr.
+41.5%
Revenue
—
Q1 FY2025
Mar 31, 2025Miss
EPS Actual
-$2.23
EPS Est.
-$0.36
EPS Surpr.
-519.4%
Revenue
—
Q4 FY2024
Nov 8, 2024Beat
EPS Actual
-$0.37
EPS Est.
-$0.46
EPS Surpr.
+19.6%
Revenue
—
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-1.60 | $-1.60 | $-1.60 | 6 |
| Q3 FY2027 | $-0.86 | $-0.86 | $-0.86 | 3 |
| Q2 FY2027 | $-0.98 | $-0.98 | $-0.98 | 5 |
| Q1 FY2027 | $-0.93 | $-0.93 | $-0.93 | 3 |
| Q4 FY2026 | $-0.92 | $-0.92 | $-0.92 | 6 |
| Q3 FY2026 | $-1.18 | $-0.70 | $-0.30 | 8 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 14, 2026 | +56.6% | $61.44 | $60.99 | -0.73% |
| ▼ Q1 FY2026 | Mar 27, 2026 | -19.1% | $54.56 | $54.10 | -0.84% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -4.3% | $82.58 | $87.01 | +5.36% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +25.5% | $31.34 | $35.90 | +14.55% |
| ▲ Q2 FY2025 | May 13, 2025 | +41.5% | $35.10 | $33.82 | -3.65% |
| ▼ Q1 FY2025 | Mar 31, 2025 | -519.4% | $40.33 | $36.41 | -9.72% |
| ▲ Q4 FY2024 | Nov 8, 2024 | +19.6% | $15.73 | $16.88 | +7.31% |
| ▼ Q3 FY2024 | Aug 9, 2024 | -11.1% | $2.75 | $2.21 | -19.64% |
Q2 FY2026-0.73%
Report Date
May 14, 2026
EPS Beat/Miss
+56.6%
Price Before
$61.44
Price After
$60.99
Q1 FY2026-0.84%
Report Date
Mar 27, 2026
EPS Beat/Miss
-19.1%
Price Before
$54.56
Price After
$54.10
Q4 FY2025+5.36%
Report Date
Nov 13, 2025
EPS Beat/Miss
-4.3%
Price Before
$82.58
Price After
$87.01
Q3 FY2025+14.55%
Report Date
Aug 12, 2025
EPS Beat/Miss
+25.5%
Price Before
$31.34
Price After
$35.90
Q2 FY2025-3.65%
Report Date
May 13, 2025
EPS Beat/Miss
+41.5%
Price Before
$35.10
Price After
$33.82
Q1 FY2025-9.72%
Report Date
Mar 31, 2025
EPS Beat/Miss
-519.4%
Price Before
$40.33
Price After
$36.41
Q4 FY2024+7.31%
Report Date
Nov 8, 2024
EPS Beat/Miss
+19.6%
Price Before
$15.73
Price After
$16.88
Q3 FY2024-19.64%
Report Date
Aug 9, 2024
EPS Beat/Miss
-11.1%
Price Before
$2.75
Price After
$2.21
Avg Beat Reaction+4.37%
Avg Miss Reaction-6.21%
Beat Rate4 / 8 quarters
Largest Move-19.64% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MNPR ends December
Monopar Therapeutics Inc. (MNPR) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-0.46 — beating the analyst consensus of $-1.06 by +56.6%. The next MNPR earnings date is expected around September 1, 2026.
Each quarter, investors track MNPR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MNPR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MNPR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MNPR earnings · 5 questionsMonopar Therapeutics Inc.'s next earnings report is expected around September 1, 2026. MNPR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MNPR historically reports after market close (AMC).
MNPR earnings datewhen is MNPR earningsMNPR next earnings datewhen does MNPR report earningsMNPR earnings calendar
▸ Source: FMP · Monopar Therapeutics Inc. SEC filings · US GAAP · Monopar Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026